TCA-Ketone Combination Compounds for Metabolic Therapy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for diseases related to abnormal metabolism face challenges in effectively administering TCA cycle intermediates and ketone bodies due to difficulties in formulation, particularly in achieving high quantities without viscosity issues and palatability problems, limiting their efficacy.
Innovation Solution
Development of combination compounds that include TCA cycle intermediates and ketone bodies, either as physical or chemical combinations, connected through glycerol or other backbone moieties, which can be metabolized to provide acetyl-CoA and propionyl-CoA, allowing for increased energy production in cells and organs like the brain and heart, and can be administered in high quantities orally.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If high quantities of TCA cycle intermediates and ketone bodies are administered, then treatment efficacy for abnormal metabolism diseases is improved, but viscosity issues and formulation difficulties worsen
Solution Approach 1:
The patent combines TCA cycle intermediates and ketone bodies into a single composition, allowing them to be administered together in high quantities without the formulation difficulties that would arise from administering each separately. This merging approach resolves the contradiction by enabling high dosages while maintaining ease of formulation.
2Quantity of substance
If high quantities of TCA cycle intermediates and ketone bodies are administered, then treatment efficacy for abnormal metabolism diseases is improved, but palatability problems worsen
Solution Approach 1:
By combining TCA cycle intermediates and ketone bodies in a single composition, the patent enables administration of high quantities that would be therapeutically effective, while the combined formulation addresses palatability issues that would arise from high doses of individual components.
3Ease of manufacture
If TCA cycle intermediates or ketone bodies are used alone, then formulation is simpler, but treatment efficacy for abnormal metabolism diseases is reduced
Solution Approach 1:
The patent merges TCA cycle intermediates and ketone bodies into a single composition, achieving treatment efficacy superior to either component alone while maintaining formulation simplicity. The combined composition allows both substances to work synergistically without the complexity of separate formulations.
4Object-affected harmful factors
If TCA cycle intermediates or ketone bodies are used alone, then palatability is better, but treatment efficacy for abnormal metabolism diseases is reduced
Solution Approach 1:
By combining TCA cycle intermediates and ketone bodies in a single composition, the patent achieves treatment efficacy superior to either component alone. The combined formulation maintains acceptable palatability while delivering the synergistic therapeutic benefit that neither substance can achieve alone.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
These combination compounds provide enhanced energy production to specific tissues and organs, offering improved treatment efficacy for diseases related to abnormal metabolism compared to using TCA cycle intermediates or ketone bodies alone, with improved flow properties and taste for direct oral administration.
Implementation Method 1
can be metabolized to provide acetyl-CoA and propionyl-CoA, allowing for increased energy production in cells and organs like the brain and heart
Data Source
AI summary
The present disclosure provides certain combination therapy technologies that are particularly useful for treating one or more diseases, disorders, or conditions that may be related to abnormal metabolism. In some embodiments, provided technologies provides combinations of TCA cycle acids and ketone bodies. In some embodiments, provided technologies provides combinations of TCA cycle acids and other carboxylic acids.